Radisens awarded €4.5M for diabetes menu development
Cork – Jun 23, 2015 – Radisens announced today that it has been awarded a €4.5m grant from the European Commission’s SME Instrument initiative. As part of the EC’s Horizon 2020 Research and Innovation programme, the €3bn SME Instrument hand-picks potentially disruptive businesses to invest and support.
“We are delighted with this significant endorsement from the EC, in support of our vision of instant testing of any high-burden chronic disease anywhere”, commented Radisens’ CEO, Jerry O’Brien. “Integrating diabetes, cardiovascular and kidney function panels onto Gemini™ will impact people’s daily lives”. Radisens will use the funds to integrate such panels on to its Gemini™ near-patient platform, giving instant results from a fraction of a drop of blood.
Near-patient blood testing is one of the fastest growing segments of the healthcare industry, fuelled by the push towards improving patient outcomes, healthcare efficiencies and quality standards. It closes the linkage between diagnostics and therapeutics, as current lab tests require days before results are available. O’Brien adds, “Radisens’ vision is that of a confirmed diagnosis, clinical counselling and prescribed therapies all within a single physician or pharmacy visit, without fear of needles or anxious days of waiting for results, thereby empowering patients to better manage their chronic disease”.